Cytosorbents Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +5.3%
EBITDA: +44.3%
EBIT: +15.7%
EPS: +34.3%
Free cash flow: +25.3%
Operating cash flow: +22.9%

Forward estimates

Revenue: +22.9%
EBITDA: —
EPS: +40.7%

Three-year CAGR

Revenue: +2.2%
EBITDA: +77.4%
EBIT: +13.5%
Net income: +60.4%
EPS: +65.8%
Free cash flow: +14.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.